CTMX
HEALTHCARECytomX Therapeutics Inc
AI Insight
What's Moving CTMX Today?
No stock-specific AI insight has been generated for CTMX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.72$8.21
$3.36
Fundamentals
Market Cap$676M
P/E Ratio—
EPS$-0.52
Dividend Yield—
Dividend / Share—
ROE-34.3%
Profit Margin-166.4%
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding217.7M
CTMX News
22 articles- CytomX Therapeutics stockholders approve share increases and board electionsInvesting.com·Jun 23, 2026
- Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?Yahoo Finance·Jun 19, 2026
- How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent DevelopmentsYahoo Finance·Jun 11, 2026
- A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial ResultsYahoo Finance·Jun 5, 2026
- REGN Expands Cancer Deal With CytomX for Bispecific TherapeuticsYahoo Finance·Jun 4, 2026
- Why Regeneron (REGN) Stock Is Trading Up TodayYahoo Finance·Jun 4, 2026
- CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of CancerYahoo Finance·Jun 3, 2026
- CytomX (CTMX) Q4 2025 Earnings TranscriptMotley Fool·Jun 2, 2026
- How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And RisksYahoo Finance·May 28, 2026
- CytomX Therapeutics to Present at Upcoming June Investor ConferencesYahoo Finance·May 21, 2026
- CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory AffairsYahoo Finance·May 18, 2026
- CytomX’s CX-801 Enters Key Early Cancer Trial Phase, Putting CTMX Back on Investor RadarTipRanks·May 16, 2026
- New Forecasts: Here's What Analysts Think The Future Holds For CytomX Therapeutics, Inc. (NASDAQ:CTMX)Yahoo Finance·May 13, 2026
- Earnings Beat: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsYahoo Finance·May 11, 2026
- CytomX (CTMX) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- CytomX Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- Small Cap or Megacap: Which Healthcare Stock Is Right for You?The Motley Fool·Apr 22, 2026
- CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment ProgressYahoo Finance·Apr 14, 2026
All 22 articles loaded
Price Data
Open$3.16
Previous Close$3.15
Day High$3.40
Day Low$3.13
52 Week High$8.21
52 Week Low$1.72
52-Week Range
$1.72$8.21
$3.36
Fundamentals
Market Cap$676M
P/E Ratio—
EPS$-0.52
Dividend Yield—
Dividend / Share—
ROE-34.3%
Profit Margin-166.4%
Debt / Equity—
Trading
Volume2.5M
Avg Volume (10D)—
Shares Outstanding217.7M
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—